Effect of Lecanemab and Donanemab in Early Alzheimer’s Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective

Alzheimer’s drug slows mental decline in trial — but is it a breakthrough?

(2022) McKenzie Prillaman   NATURE

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donanemab in Early Alzheimer’s Disease

(2021) Mark A. Mintun et al.   NEW ENGLAND JOURNAL OF MEDICINE

Alzheimer’s Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence

(2018) Maya L. Gosztyla et al.   JOURNAL OF ALZHEIMERS DISEASE

Endocytic uptake of monomeric amyloid-β peptides is clathrin- and dynamin-independent and results in selective accumulation of Aβ(1–42) compared to Aβ(1–40)

(2017) Emelie Wesén et al.   Scientific Reports

ApoE-isoform-dependent cellular uptake of amyloid-β is mediated by lipoprotein receptor LR11/SorLA

(2015) Ryuji Yajima et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Protective alleles and modifier variants in human health and disease

(2015) Andrew R. Harper et al.   NATURE REVIEWS GENETICS

Differences in the Cellular Uptake and Intracellular Itineraries of Amyloid Beta Proteins 40 and 42: Ramifications for the Alzheimer’s Drug Discovery

(2012) Rajesh S. Omtri et al.   MOLECULAR PHARMACEUTICS

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

(2012) Thorlakur Jonsson et al.   NATURE

Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide

(2009) X. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA